Pembrolizumab plus Chemotherapie als Erstlinientherapie beim fortgeschrittenen Ösophaguskarzinom (KEYNOTE-590)Pembrolizumab plus chemotherapy as first-line treatment in advanced oesophageal cancer (KEYNOTE-590)

被引：0
|
作者：
Milan Hartmann
Thomas Zander
Hakan Alakus
机构：
[1] Universitätsklinikum Köln (AöR),Klinik und Poliklinik für Allgemein‑, Viszeral‑, Tumor
[2] Universitätsklinikum Köln, und Transplantationschirurgie
来源：
Der Onkologe | 2022年 / 28卷 / 5期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：436 / 437
页数：1
相关论文
共 50 条
  • [41] First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study
    Qin, Shukui
    Bai, Yuxian
    Li, Jin
    Pan, Hongming
    Luo, Suxia
    Qu, Yanli
    Ye, Feng
    Yang, Lin
    Liu, Tianshu
    Li, Wei
    Chen, Xi
    Yang, Jianwei
    Ying, Jieer
    Lin, Xiaoyan
    Zhao, Lin
    Liang, Xinjun
    Mao, Yixiang
    Guo, Run
    Zuo, Yi
    Bordia, Sonal
    Li, Shouguo
    ADVANCES IN THERAPY, 2025, : 1892 - 1906
  • [42] First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
    Shunji Takahashi
    Nobuhiko Oridate
    Kaoru Tanaka
    Yasushi Shimizu
    Yasushi Fujimoto
    Koji Matsumoto
    Tomoya Yokota
    Tomoko Yamazaki
    Masanobu Takahashi
    Tsutomu Ueda
    Nobuhiro Hanai
    Hironori Yamaguchi
    Hiroki Hara
    Tomokazu Yoshizaki
    Ryuji Yasumatsu
    Masahiro Nakayama
    Kiyoto Shiga
    Takashi Fujii
    Kenji Mitsugi
    Kenichi Takahashi
    Nijiro Nohata
    Burak Gumuscu
    Ramona F. Swaby
    Makato Tahara
    International Journal of Clinical Oncology, 2022, 27 : 1805 - 1817
  • [43] First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
    Takahashi, Shunji
    Oridate, Nobuhiko
    Tanaka, Kaoru
    Shimizu, Yasushi
    Fujimoto, Yasushi
    Matsumoto, Koji
    Yokota, Tomoya
    Yamazaki, Tomoko
    Takahashi, Masanobu
    Ueda, Tsutomu
    Hanai, Nobuhiro
    Yamaguchi, Hironori
    Hara, Hiroki
    Yoshizaki, Tomokazu
    Yasumatsu, Ryuji
    Nakayama, Masahiro
    Shiga, Kiyoto
    Fujii, Takashi
    Mitsugi, Kenji
    Takahashi, Kenichi
    Nohata, Nijiro
    Gumuscu, Burak
    Swaby, Ramona F.
    Tahara, Makato
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (12) : 1805 - 1817
  • [44] Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.
    Plimack, Elizabeth R.
    Rini, Brian, I
    Stus, Viktor
    Gafanov, Rustem
    Waddell, Tom
    Nosov, Dmitry
    Pouliot, Frederic
    Soulieres, Denis
    Melichar, Bohuslav
    Vynnychenko, Ihor
    Azevedo, Sergio Jobim
    Borchiellini, Delphine
    McDermott, Raymond S.
    Bedke, Jens
    Tamada, Satoshi
    Yin, Lina
    Chen, Mei
    Molife, L. Rhoda
    Atkins, Michael B.
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Preliminary safety data from KEYNOTE-059: Pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer
    Fuchs, Charles S.
    Ohtsu, Atsushi
    Tabernero, Josep
    Van Cutsem, Eric
    Wang, Jiang Dian
    Lam, Baohoang
    Dalal, Rita
    Koshiji, Minori
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] Pembrolizumab plus chemotherapy as first-line treatment in patients with HER2 negative advanced oesogastric adenocarcinoma
    Duval, Martin
    Zaanan, Aziz
    BULLETIN DU CANCER, 2024, 111 (05) : 431 - 432
  • [47] Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
    Zhang, Jie
    Wu, Di
    Zhang, Ziran
    Long, Jieran
    Tian, Guangming
    Wang, Yang
    Ma, Xiangjuan
    Chen, Xiaoling
    Han, Jindi
    Hu, Weiheng
    Dai, Ling
    Nie, Jun
    Fang, Jian
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2021, 20
  • [48] Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.
    Gadgeel, Shirish M.
    Stevenson, James
    Langer, Corey J.
    Gandhi, Leena
    Borghaei, Hossein
    Patnaik, Amita
    Villaruz, Liza Cosca
    Gubens, Matthew A.
    Hauke, Ralph J.
    Yang, James Chih-Hsin
    Sequist, Lecia V.
    Bachman, Robert D.
    Ge, Joy Yang
    Raftopoulos, Harry
    Papadimitrakopoulou, Vassiliki
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC
    Cortes, J.
    Cescon, D. W.
    Rugo, H. S.
    Im, S-A.
    Yusof, M. Md
    Gallardo, C.
    Lipatov, O.
    Barrios, C. H.
    Perez-Garcia, J.
    Iwata, H.
    Masuda, N.
    Otero, M. Torregroza
    Gokmen, E.
    Loi, S.
    Guo, Z.
    Zhou, X.
    Karantza, V.
    Pan, W.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1289 - S1290
  • [50] Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799.
    Jabbour, Salma K.
    Lee, Ki Hyeong
    Frost, Nicolaj
    Kowalski, Dariusz
    Breder, Valeriy Vladimirovich
    Pollock, Theodore
    Reguart, Noemi
    Houghton, Baerin
    Quantin, Xavier
    Keller, Steven M.
    Liu, Hong
    Piperdi, Bilal
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345